## CLAIMS

- Peptide composition characterized in that it comprises a polyprotein NS3/NS4 of the hepatitis C virus, as well as a polypeptide NS5b of the hepatitis C virus.
  - 2. Peptide composition according to claim 1, characterized in that NS3 and/or NS4 and/or NS5b originate from viruses of different genotypes.
- 3. Peptide composition according to claim 1, characterized in that NS3, NS4 and NS5b originate from a virus of the same genotype, preferably genotype 1b.
- 4. Expression vector characterized in that it comprises a nucleotide sequence coding for the polyprotein NS3/NS4 and a nucleotide sequence coding for the polypeptide NS5b, as well as the means necessary to their expression.
- 5. Expression vector according to claim 4, characterized in that the nucleotide sequences code for a polyprotein and a polypeptide originating from viruses of different genotypes.
- 6. Expression vector according to claim 4, characterized in that the nucleotide sequences code for a polyprotein and a polypeptide originating
  25 from a virus of the same genotype, preferably the genotype 1b.
  - 7. Expression vector according to any one of claims 4 to 6, characterized in that this vector is an adenovirus.
- 8. Expression vector according to claim 7, characterized in that the genome of the adenovirus is modified so as to replace the EI region by the expression cassette CMV-NS3-NS4 and to replace the E3 region by the expression cassette SV40- NS5b.

- 9. Expression vector according to any one of claims 4 to 6, characterized in that this vector is a poxvirus.
- 10. Expression vector according to claim 9, characterized in that the genome of the poxvirus is modified so as to insert the expression cassette ph5r-NS3-NS4 and to insert the expression cassette p7.5- NS5b.
  - 11. Microorganism or host cell transformed by an expression vector as defined in any one of claims 4 to 10.

10

15

20

5

- 12. Use of a peptide composition as defined in any one of claims 1 to 3, or of an expression vector as defined in any one of claims 4 to 10, or of an expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the polypeptide NS5b, or nucleotide sequences coding for said polyprotein NS3/NS4 and said polypeptide NS5b, said nucleotide sequences corresponding to the sequences contained in the expression vectors as defined in any one of claims 4 to 10, placed under the control of elements necessary to an expression constitutive of and/or inducible from said peptides, for the preparation of a medicament intended for the inhibition, prevention or control of an infection caused by the hepatitis C virus in an animal, preferably human.
- 13. Pharmaceutical composition, in particular vaccine, comprising as active ingredient the peptide composition as defined in claims 1 to 3, or an expression vector as defined in any one of claims 4 to 10, or an expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the polypeptide.

30

14. Pharmaceutical composition according to claim 13, characterized in that it also comprises a pharmaceutically appropriate vehicle.

15. Pharmaceutical kit, in particular vaccinal, characterized in that it comprises at least one expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 and at least one expression vector comprising a nucleotide sequence coding for the Polypeptide NS5b.

5

16. Pharmaceutical kit, in particular vaccinal, characterized in that it comprises at least one expression vector as defined in claim 7 or 8 and at least one expression vector as defined in claim 9 or 10.

10

17. Pharmaceutical kit, in particular vaccinal, comprising at least one expression vector as defined in any one of claims 4 to 10, or at least one expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the Polypeptide NS5b, and

15

- (i) at least one peptide composition as defined in claims 1 to 3 or
- (ii) at least one nucleotide sequence coding for the polyprotein NS3/NS4 and for the polypeptide NS5b.